Vedanta Biosciences has raised a $106.5M funding round to develop therapies for allergies and liver disease.
The Bill & Melinda Gates Foundation and Pfizer were among the main investors.
Vedanta Biosciences develops oral therapies based on bacteria isolated from the human microbiome.
- These therapies are used to treat allergies, liver disease, inflammatory bowel diseases, and C. difficile infections.
- The company claims it has over 70 patents.
- The funding was co-led by new investors AXA IM Alts and The AMR Action Fund, with participation from the Bill & Melinda Gates Foundation, Pfizer, Skyviews Life Science, Reimagined Ventures, Fiscus Ventures, PEAK6, Atlantic Neptune, K2 HealthVentures, Korea Investment Partners, PureTech Health, Revelation Partners, QUAD Investment Management, Seventure Partners, and Hambro Perks.
- The company is based in Cambridge, Massachusetts.
